|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
CN114867726B
(zh)
|
2019-10-28 |
2023-11-28 |
默沙东有限责任公司 |
Kras g12c突变体的小分子抑制剂
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
CN116368130A
(zh)
|
2020-08-28 |
2023-06-30 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
US20240109893A1
(en)
*
|
2020-12-22 |
2024-04-04 |
Shanghai Kechow Pharma, Inc. |
Preparation and application method of heterocyclic compounds as kras inhibitor
|
|
CA3210383A1
(en)
*
|
2021-03-12 |
2022-09-15 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
CN115141215B
(zh)
*
|
2021-03-30 |
2023-09-15 |
上海德琪医药科技有限公司 |
Kras g12d蛋白抑制剂和其用途
|
|
JP2024517693A
(ja)
*
|
2021-04-29 |
2024-04-23 |
アムジエン・インコーポレーテツド |
２－アミノベンゾチアゾール化合物及びその使用方法
|
|
JP2024517695A
(ja)
*
|
2021-04-29 |
2024-04-23 |
アムジエン・インコーポレーテツド |
複素環式化合物及び使用方法
|
|
JP2024520000A
(ja)
*
|
2021-05-24 |
2024-05-21 |
上海瓔黎薬業有限公司 |
含窒素複素環化合物、その製造方法及び使用
|
|
WO2023284881A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as kras g12d inhibitors
|
|
TW202328124A
(zh)
*
|
2021-08-18 |
2023-07-16 |
大陸商北京加科思新藥研發有限公司 |
1,4-氧雜氮雜環庚烷衍生物及其用途
|
|
US20240409558A1
(en)
*
|
2021-09-13 |
2024-12-12 |
Biomea Fusion, Inc. |
Irreversible inhibitors of kras
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
WO2023072188A1
(zh)
*
|
2021-10-29 |
2023-05-04 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
JP2024543879A
(ja)
*
|
2021-11-24 |
2024-11-26 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｋｒａｓ変異型タンパク質の小分子阻害剤
|
|
EP4405337A4
(en)
*
|
2021-11-30 |
2025-11-26 |
Beta Pharma Inc |
Fused pyrimidine derivatives as kras oncoprotein inhibitors
|
|
WO2023114733A1
(en)
*
|
2021-12-13 |
2023-06-22 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2023137223A1
(en)
*
|
2022-01-17 |
2023-07-20 |
Newave Pharmaceutical Inc. |
Pan-kras inhibitors and uses thereof
|
|
CN118556063A
(zh)
*
|
2022-01-21 |
2024-08-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
IL314486A
(en)
*
|
2022-02-03 |
2024-09-01 |
Mirati Therapeutics Inc |
Quinazoline compounds inhibit PAN-KRAS
|
|
AU2023218370B2
(en)
|
2022-02-09 |
2024-11-28 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
AU2023222076A1
(en)
*
|
2022-02-16 |
2024-08-15 |
Amgen Inc. |
Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
KR20240163107A
(ko)
|
2022-03-11 |
2024-11-18 |
컴쿼트 바이오사이언시즈 인크. |
헤테로환 화합물 및 이의 용도
|
|
WO2023215802A1
(en)
*
|
2022-05-04 |
2023-11-09 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
IL317601A
(en)
|
2022-05-25 |
2025-02-01 |
Quanta Therapeutics Inc |
Pyrimidine-based modulators and their uses
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
JP2025524597A
(ja)
*
|
2022-07-07 |
2025-07-30 |
ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
複素環式化合物、その組成物、及びそれによる処置方法
|
|
CA3261681A1
(en)
|
2022-08-05 |
2024-02-08 |
Kumquat Biosciences Inc. |
HETEROCYCLIC COMPOUNDS AND THEIR USES
|
|
CN117624170A
(zh)
*
|
2022-08-24 |
2024-03-01 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
WO2024044667A2
(en)
*
|
2022-08-26 |
2024-02-29 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2024045066A1
(en)
*
|
2022-08-31 |
2024-03-07 |
Nikang Therapeutics, Inc. |
Alkylidene carbamate as kras inhibitors
|
|
KR20250057027A
(ko)
*
|
2022-09-07 |
2025-04-28 |
브리스톨-마이어스 스큅 컴퍼니 |
Kras g12d 억제제
|
|
WO2024054625A2
(en)
*
|
2022-09-08 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
|
|
TW202416976A
(zh)
*
|
2022-09-16 |
2024-05-01 |
大陸商南京明德新藥研發有限公司 |
含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物
|
|
WO2024061365A1
(zh)
*
|
2022-09-22 |
2024-03-28 |
成都奥睿药业有限公司 |
嘧啶并环类化合物及其制备方法与用途
|
|
WO2024063576A1
(ko)
*
|
2022-09-23 |
2024-03-28 |
일동제약(주) |
Kras 저해 물질로서 신규한 퀴나졸린 화합물
|
|
JP2025536369A
(ja)
|
2022-10-21 |
2025-11-05 |
リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド |
Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
|
|
EP4631942A1
(en)
|
2022-10-21 |
2025-10-15 |
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
Pan-kras degrading agent, and preparation method therefor and use thereof
|
|
WO2024112654A1
(en)
|
2022-11-21 |
2024-05-30 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
WO2024192424A1
(en)
|
2023-03-15 |
2024-09-19 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024207892A1
(zh)
*
|
2023-04-04 |
2024-10-10 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
KR20260010430A
(ko)
*
|
2023-05-15 |
2026-01-20 |
미라티 테라퓨틱스, 인크. |
Kras g12s 및 g12c 억제제
|
|
WO2025019823A1
(en)
*
|
2023-07-20 |
2025-01-23 |
Merck Sharp & Dohme Llc |
Small molecule protein degraders of kras g12d mutant
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
AU2024323424A1
(en)
|
2023-08-17 |
2026-03-05 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025051242A1
(zh)
*
|
2023-09-08 |
2025-03-13 |
泰励生物科技（上海）有限公司 |
Ras抑制剂
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025085748A1
(en)
|
2023-10-20 |
2025-04-24 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
TW202545934A
(zh)
*
|
2024-02-05 |
2025-12-01 |
日商安斯泰來製藥股份有限公司 |
包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體
|
|
WO2025170938A1
(en)
*
|
2024-02-06 |
2025-08-14 |
Windermere Therapeutics, Inc. |
Kras(g12d) inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025218811A1
(zh)
*
|
2024-04-19 |
2025-10-23 |
领泰生物医药(绍兴)有限公司 |
pan-KRAS靶向蛋白降解剂及其制备方法和应用
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|